MedPath

Effect of Fecal Microbiota Transplantation (FMT) in Pediatric Functional Gastrointestinal Disorders

Not Applicable
Recruiting
Conditions
Functional Gastrointestinal Disorders
Interventions
Biological: FMT
Drug: Conventional drugs
Registration Number
NCT05753774
Lead Sponsor
Biao Zou
Brief Summary

Safety and efficacy of FMT in Pediatric Functional Gastrointestinal Disorders

Detailed Description

The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease states. Functional gastrointestinal disorders (FGIDs), also known as brain-intestinal interaction abnormalities, are associated with dynamic disorders, high visceral sensitivity, changes in mucosal and immune functions, changes in intestinal flora, and abnormal central nervous system regulatory functions. Fecal microbiota transplantation (FMT) is a process in which a presumed healthy and diverse microbiome is transplanted to a patient using a nasogastric tube, colonoscopy, or enema, or Fecal capsule to remodel the intestinal flora balance. At present, there are few clinical studies on the treatment of FGID in children with FMT. The investigators prospectively enrolled functional children who met the Rome IV standard, and divided them into conventional treatment group or FMT group with open choice. The efficacy of the two groups was collected and compared at different time points, and the flora of children in the FMT group before and after treatment was collected to monitor FMT-related adverse reactions

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • The diagnosis and classification of patients with FGIDs were in accordance with the ROME IV criteria for children
Exclusion Criteria
  • organic gastrointestinal disease (as established by medical history, blood routine, biochemistry, c-reaction protein, erythrocyte sedimentation rate, and fecal routine examinations.)
  • other chronic disease
  • growth failure

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
fecal microbiota transplantationFMTFecal microbiota transplantation routes include the upper digestive tract, lower digestive tract, or oral fecal microbiota transplantation capsules
Conventional drug interventionConventional drugsConventional drugs include: probiotics and omeprazole, and cyproheptadine and moxapride.
Primary Outcome Measures
NameTimeMethod
The efficacy of FMT in pediatric FGID4 weeks and 8 weeks

change in Gastrointestinal Symptom Rating Scale (GSRS), validated scale of GI symptoms. The items are scored between 1 and 7, where 1 corresponds to "no discomfort at all" and 7 to "very severe discomfort" from the symptom.

self-reported severity of pain4 weeks and 8 weeks

change in self-reported severity of pain is defined as at least two Faces Pain Score (Wong-Baker Pain Rating Scale;0-no hurt,10-hurts worst for pain)

Secondary Outcome Measures
NameTimeMethod
Mean number of bowel movements per week4 weeks and 8weeks

change in the mean number of bowel movements per week

Irritable bowel syndrome Symptom Severity Scale (IBS-SSS)4 weeks and 8 weeks

IBS-SSS is a visual assessment scale (VAS) rating from 0 to 100, with total scores ranging from 0 to 500. Mild, moderate and severe cases are indicated by scores of 75 to 175, 175 to 300 and \> 300.

gut microbial4 weeks and/or 8 weeks

Fecal 16S RNA or macrogene sequencing was performed. Fecal samples were obtained from donor and recipient. The fecal samples and isolated microbiota samples were frozen immediately and underwent DNA extraction using standard methods.

Adverse events2 weeks , 4 weeks and 8 weeks

All possible adverse events after FMT: fever, abdominal pain, infectious diseases and others

Change in Pittsburgh sleep quality index (PSQI)4 weeks and 8 weeks

PSQI assesses sleep quality in children. A higher score indicates poorer sleep quality. The PSQI will be assessed from baseline to 1 weeks and from baseline to 1 month. PSQI is scored from 0 to 21 points. The higher the score, the worse the sleep. PSQI≥8 was poor sleep quality, and 7 was the cut-off value

Bristol stool scale4 weeks and 8 weeks

Change in stool consistency assessed using the Bristol Stool Form Scale. The Bristol stool classification divides stool into seven categories. Types 1 and 2 indicate constipation; Types 3 and 4 are ideal for bowel movements, while types 5 to 7 indicate possible diarrhea.

Trial Locations

Locations (1)

Tongji Hospital

🇨🇳

Wuhan, China

© Copyright 2025. All Rights Reserved by MedPath